OXFORD, UK--(Marketwire - June 03, 2010) -
Mirada Medical Limited (“Mirada” or “the Company”) Launch of Caseaccess - A New Product for Improved PET-CT Image Reporting ~ Participation at Society of Nuclear Medicine Annual Conference, Salt Lake City, Utah, 5-9 June, 2010 ~
Oxford, UK and Ohio, US 3 June 2010: Mirada Medical Limited, the profitable and fast growing international company focused on advanced oncology imaging, is pleased to announce today the global launch of Caseaccess, a new software solution for specialists globally. Caseaccess combines Mirada Medical’s state-of-the-art fusion image analysis software with the world’s latest online image visualisation technologies to provide clinical decision makers and referring or primary care physicians with remote access to their patient’s PET-CT and SPECT-CT scans and reports via fast, richly featured multi- modal quantitative imaging software.
Mirada Medical aims to provide readers with greater clinical certainty in the diagnosis and treatment of disease by providing enhanced 3D multi-modal imaging together with powerful quantification tools that can be used to assess how pathology, for example malignant tumours, are responding to treatment regimes. Mirada’s products were launched into the global marketplace in 2001 and are currently sold through leading international imaging companies including Siemens, Sectra, Carestream, Vital Images and McKesson. The Company’s technology was founded by one of the world’s leading imaging scientists, Professor Sir Michael Brady, at Oxford University’s Medical Vision Laboratory centre.
Caseaccess is Mirada’s third product to be launched into the global marketplace in the last 12 months. It allows efficient dissemination of patient imaging information and reporting via sophisticated technology that takes image data from the centre where the patient was scanned and makes this available to the referring physician regardless of where the referrer is located. This provides significant technological advantages over currently available report distribution mechanisms. These often use slow and unreliable methods, such as posting a CD containing the image data and report, or relaying patient information via inefficient web based packages and tools that prevent the referring physician from being able to fully and clearly understand the patient’s condition.
Mirada Medical will showcase its latest and industry leading developments at this year’s Society of Nuclear Medicine Annual Conference, held 5-9 June 2010, in Salt Lake City, Utah. Mirada Medical’s team will be located at booth No. 1613.
Commenting on today’s announcement, Chief Technology Officer, Dr Timor Kadir said: “The purpose of Healthcare IT is to increase workflow efficiency while assisting clinical users to obtain the best possible quality of information from the raw data. Both imaging centres and referrers will benefit from Mirada’s new Caseaccess product. Caseaccess reliably and rapidly disseminates all of the available data and information which has been acquired, certainly boosting productivity and enabling an improved level of communication and understanding, particularly for the referring physician.”
Hugh Bettesworth, CEO of Mirada Medical, added: “We are delighted to be launching another new product that supports decision makers and the ongoing management of complex disease such as cancer. Mirada continues to be clinically and commercially focused and aims to deliver better healthcare solutions in the critical field of cancer imaging. We are penetrating new markets internationally and enjoying a growing presence in our key US market.”
For more information, please contact: Mirada Medical Europe: Hugh Bettesworth, CEO tel: +44 (0) 1865 811172 US: Joan Washburn tel: +1 865 696 7809 M:Communications Mary-Jane Elliott / Emma Thompson tel: +44 (0)20 7920 2345 Healthcare@mcomgroup.com About Mirada Medical
Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with an enhanced software package for the quantification of images, typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.
Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.
The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.
About Caseaccess
Caseaccess is the latest innovation in case reporting, allowing hospitals to share PET/CT data securely with referring physicians anywhere and at any time. No matter where the referrer is physically located, this state of the art PET/CT reporting solution provides instant real-time access to their patients’ case report, including all images and quantifications. Mirada’s Caseaccess may be used in conjunction with any vendors’ data when read using any vendors’ reading software. When used with Mirada’s ground breaking XD3 case analysis software, this solution is even more powerful: just one click sends an email link to the case information directly to the referring physician, together with an optional text message notification.
About Society of Nuclear Medicine (SNM) Annual Conference
The 57th Annual Meeting will take place on June 5-9 2010 at the Salt Palace Convention Center in Salt Lake City, Utah. SNM is an international scientific and professional organization of more than 17,000 physicians, technologists, physicists, chemists and radiopharmacists dedicated to improving health care by advancing molecular imaging and therapy. The meeting features more than 1,600 scientific papers and posters submitted by scientists, physicians and technologists in the molecular imaging and nuclear medicine fields. In addition, more than 170 manufacturers attend the meeting to showcase and demonstrate the most technologically advanced molecular imaging and nuclear medicine equipment.
[HUG#1421381]
